Biosimilarity Assessment of 2 Filgrastim Therapeutics in Healthy Volunteers
| Autor: | Seyed Reza Khandoozi, Majid Shahbazi, Hossein Amini |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Filgrastim Neutrophils Injections Subcutaneous Cmax Pharmaceutical Science 030226 pharmacology & pharmacy 03 medical and health sciences Young Adult 0302 clinical medicine Pharmacokinetics Hematologic Agents medicine Humans Pharmacology (medical) Biosimilar Pharmaceuticals Cross-Over Studies business.industry Biosimilar Crossover study Tolerability 030220 oncology & carcinogenesis Anesthesia Pharmacodynamics Area Under Curve Absolute neutrophil count business medicine.drug Half-Life |
| Zdroj: | Clinical pharmacology in drug developmentReferences. 10(4) |
| ISSN: | 2160-7648 |
| Popis: | This study aimed to compare the pharmacokinetic, pharmacodynamic, and safety profiles of a proposed biosimilar and innovator filgrastim therapeutics in healthy volunteers. In a crossover design, 23 subjects received a single subcutaneous injection of 300-µg filgrastim, followed by a 7-day washout period. Assessed pharmacokinetic parameters were the maximum observed filgrastim serum concentration (Cmax ), time to reach Cmax (tmax ), the area under the concentration-time curve (AUC), and elimination half-life. Pharmacodynamics were assessed by the maximum observed absolute neutrophil count effect (Emax ), tmax,E (time to reach Emax ), and the area under the effect of the absolute neutrophil count -time curve. The test/reference ratio (90% confidence intervals) of Cmax of 0.992 (0.860-1.143), AUC0-inf of 0.995 (0.891-1.111), Emax of 0.952 (0.841, 1.078), and area under the effect of the absolute neutrophil count -time curve from time zero to 96 hours of 0.939 (0.854-1.032), were all well within the predefined equivalence boundaries of 80% and 125%. Obtained values for tmax (∼4 hours), tmax,E (∼15 hours), and elimination half-life (∼3.5 hours) were comparable between 2 treatment groups. The local tolerability and incidence of adverse events were comparable, with no clinically meaningful difference between biosimilar and innovator products. Altogether, the results suggested a high similarity of the proposed biosimilar to the innovator filgrastim in healthy volunteers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text